RNS Number: 6495 C Silence Therapeutics PLC 18 June 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6434 C Silence Therapeutics PLC 18 June 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 600,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
Silence Therapeutics Plc (SLN.L) Announced that it has entered into a collaboration with Genomics England Limited (Genomics England) for the investigation of novel targets involved in human disease.
LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has entered into a collaboration with Genomics England Limited for the investigation of novel targets involved in human disease.. Genomics England has generated a unique database of...
RNS Number: 6073 Z Silence Therapeutics PLC 20 May 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 60,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 0086 Z Silence Therapeutics PLC 14 May 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 128,078 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 4755 X Silence Therapeutics PLC 30 April 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 61,626 new ordinary shares of 5 p each following the exercise of 60,000 share options under the...
RNS Number: 2859 X Silence Therapeutics PLC 26 April 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 242,222 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 1560 X Silence Therapeutics PLC 25 April 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 1,626 new ordinary shares of 5 p each following the exercise of share options under the 2018...
Silence Therapeutics Plc (SLN.L) Announced that Iain Ross has joined as a Non-Executive Director and Chairman of the Board of Directors with immediate effect. The company added that James Ede-Golightly has joined as a NonExecutive Director and that Stephen Parker is stepping down as a Non-Executive Director, both with immediate effect.
RNS Number: 0194 X Silence Therapeutics PLC 25 April 2019 Silence Therapeutics Strengthens Board with Key Appointments. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that Iain Ross has joined as a Non-Executive Director and...
Silence Therapeutics (SLN.L) 57.7p £41.05m The specialist n the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announced the appointment of Rob Quinn as full time CFO, effective immediately. Dr. Quinn has served as the Interim CFO of Silence since Jan 2019, having been the Head of Financial Planning and Analysis at the Company for the two years prior to this. He has a wealth of both financial and scientific experience and before joining Silence he held a senior role at GSK, as Area Finance Director for Africa & Developing Countries. Dr. Quinn is a Chartered Accountant and qualified at Deloitte, including time spent working in corporate finance advisory within the life sciences sector. He also holds a PhD in Biochemistry from the University of Manchester. Dr. Quinn will not be appointed to the Board of Directors
Silence Therapeutics Plc (SLN.L) Announced that its annual report and financial statements for the year ended 31 December 2018 is available for download on the company's website www.silence-therapeutics.com. The Annual Report and Accounts will be posted to shareholders on or before 21 May 2019. Further, the company announced that this year's Annual General Meeting (AGM) of the company will be held on 25 June 2019. The Notice of the AGM will be posted to shareholders on or before 21 May 2019, when it will also be made available on the company's website.
RNS Number: 5503 W Silence Therapeutics PLC 18 April 2019 Silence Therapeutics Notice of Annual General Meeting and publication of Annual Report. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that its annual report and financial...
LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce the appointment of Rob Quinn as full time Chief Financial Officer, effective immediately.. He has a wealth of both financial and scientific experience and before joining Silence he held a...
Silence Therapeutics Plc (SLN.L) Announced the appointment of Giles Campion, MD as Head of R&D and Chief Medical Officer, effective 1 June 2019.
RNS Number: 3512 W Silence Therapeutics PLC 16 April 2019. Silence Therapeutics Announces Board Change. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces today that Dr.
LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce the appointment of Giles Campion, MD as Head of R&D and Chief Medical Officer, effective 1 June 2019.. During this time the company signed a collaboration agreement with GSK worth up to $655...
RNS Number: 1253 V Silence Therapeutics PLC 04 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Silence Therapeutics (SLN.L) 41p £29.14m Silence Therapeutics “announced that a Clinical Trial Application (CTA) for the Company's lead candidate SLN124 has been submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA). SLN124, which has been shown to lower serum iron levels, modulate tissue iron distribution and ameliorate anemia in preclinical models for ß-Thalassemia and Hereditary Hemochromatosis (HH), represents a highly promising therapeutic candidate medicine for patients with iron overload disorders, such as ß -Thalassemia, Myelodysplastic syndrome (MDS) and HH. Subject to approval from the MHRA, Silence intends to begin a Phase Ib First-in-Human study in ß -Thalassemia and MDS patients, with the first patient expected to enter the study in Q3 2019. In Jan 2019, SLN124 was granted Orphan Drug Designation by the Committee for Orphan Medicinal Products
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    71.07M
Watchlist